Every S-1 that HCW Biologics Inc. (HCWB) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A S-1 covers the registration statement a company files to sell shares publicly, so if you follow HCWB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full HCWB filings page.
HCW Biologics Inc. (HCWB) filed Amendment No. 1 to its Registration Statement on Form S-1 (Registration No. 333-298452). The company states this is an exhibits-only filing, meaning the substantive terms of the underlying registration statement remain unchanged and only the exhibit list and related materials are being updated. The amendment adds or updates various corporate, financing, warrant, equity plan, licensing and debt-related agreements as exhibits, along with legal opinions and Inline XBRL files, while expressly leaving the rest of the registration statement as previously filed.
HCW Biologics Inc. (HCWB), a clinical-stage immunotherapy company, has filed a Form S-1 to register the resale of up to 1,237,364 shares of common stock by selling stockholders. These include 218,682 shares issued in a July 29, 2026 PIPE financing, up to 400,000 shares issuable upon exercise of pre-funded warrants at $0.0001 per share, and up to 618,682 shares issuable upon exercise of common warrants at $2.585 per share, subject to stockholder approval.
The July 2026 PIPE generated approximately $1.6 million in gross proceeds for HCWB, with participation by its CEO, board chair and an executive. HCWB will not receive proceeds from resale of registered shares but may receive up to about $1.6 million if the common warrants are approved and exercised for cash, to be used for general corporate purposes.
As of August 20, 2026, HCWB had 1,836,324 shares outstanding, and its stock closed at $2.52 on August 17, 2026, after a 1-for-6 reverse split effective June 30, 2026. The filing highlights significant risks, including potential dilution from warrant exercises, substantial resale overhang, past Nasdaq listing compliance issues, material weaknesses in internal controls, restated EPS for the quarter ended March 31, 2026, and the speculative nature of investing in an early-stage biopharmaceutical issuer.
HCW Biologics Inc. filed Amendment No. 1 to its Registration Statement on Form S-1 as an exhibits-only update. The amendment adds and organizes legal, governance, financing, warrant, equity incentive, and related agreements as exhibits, along with opinion letters, consents, and Inline XBRL data files.
The company states that the remainder of the S-1 registration statement is unchanged and therefore omitted from this amendment. The filing is signed by Founder and Chief Executive Officer Hing C. Wong and other directors and officers, confirming authorization of this administrative update.
HCW Biologics Inc. has filed an S-1 to register the resale of up to 5,693,950 shares of common stock issued or issuable from a May 2026 private placement (the PIPE Transaction). These shares include stock already issued plus shares underlying pre-funded warrants and May 2026 common warrants.
The company previously raised approximately $4.0 million in gross proceeds from selling 2,846,975 units at $1.405 per unit, each unit including one share or pre-funded warrant and one common warrant. HCW Biologics will not receive proceeds from selling stockholders’ resales, but could receive up to about $3.6 million if the May 2026 common warrants are exercised for cash.
The filing highlights HCW Biologics’ clinical-stage immunotherapy pipeline, commercial-ready cell-therapy reagents, and its status as an emerging growth and smaller reporting company. It also describes Nasdaq bid-price compliance requirements, potential reverse stock split plans, material weaknesses in internal control over financial reporting, and the dilution and volatility risks tied to warrant exercises and additional equity issuance.
HCW Biologics Inc. is registering up to 13,625,304 shares of common stock, or the same number of pre-funded warrants plus 13,625,304 underlying shares, in a reasonable best efforts public offering targeting gross proceeds of about $5.6 million. The assumed price is $0.411 per share, matching the April 20, 2026 Nasdaq close. Shares outstanding would rise from 6,734,104 to 20,359,408 if only stock is sold, creating substantial dilution; management estimates new investors would see about $0.08 per-share dilution at the assumed price. Net proceeds of roughly $5.2 million are expected to fund clinical development of lead programs such as HCW9302, research and development, business development and general corporate purposes. The deal has no minimum, so the company may receive significantly less if fewer securities are sold. The company is currently working to address Nasdaq bid-price compliance through a May 5, 2026 hearing while remaining an emerging growth and smaller reporting company.
HCW Biologics Inc. is registering up to 13,625,304 shares of common stock, up to 13,625,304 pre-funded warrants, and 13,625,304 shares underlying those warrants in a primary offering for gross proceeds of about $5.6 million on a reasonable best efforts basis.
The assumed offering price is $0.411 per share, matching the April 20, 2026 Nasdaq close. Common shares outstanding are 6,734,104 and would rise to 20,359,408 if only stock (no pre-funded warrants) is sold. Existing holders face immediate dilution, and there is no minimum raise or escrow, so the company may collect far less than the maximum.
Pre-funded warrants are aimed at investors otherwise exceeding 4.99% or 9.99% ownership caps and carry a $0.0001 exercise price with no expiry. Net proceeds are expected to be about $5.2 million at the full size, to fund clinical and preclinical development, including HCW9302 trials, R&D, marketing and general corporate uses. The company has recent Nasdaq bid-price and equity compliance history and a May 5, 2026 hearing regarding minimum bid price.
HCW Biologics Inc. is filing an S-1 to offer up to 7,691,124 Units, each made up of one share of common stock (or a pre-funded warrant) plus one common stock warrant, on a reasonable best efforts basis for assumed gross proceeds of about $5 million.
The offering has no minimum, no escrow and may close with significantly less capital raised, which the company plans to use mainly for clinical development of HCW9302, broader R&D, business development, IP expansion and general corporate purposes. New investors face immediate dilution, and common stock warrants will only be exercisable if required shareholder approval is obtained.
The prospectus highlights substantial doubt about HCW Biologics’ ability to continue as a going concern, significant past-due payables including construction and legal obligations, and a history of Nasdaq listing compliance issues, though the company recently regained compliance with the equity rule. It also details a restructured license with Trimmune for HCW11-006, providing a $3.5 million upfront package split between cash and equity, and describes early-stage clinical progress for autoimmune indications.
HCW Biologics Inc. filed Amendment No. 1 to its Form S-1 registration statement as an exhibits-only update. The amendment leaves the substantive disclosure in the original S-1 unchanged and primarily refreshes and compiles the exhibit index, including various corporate governance, financing, licensing and commercial agreements.
The filing states that effectiveness will occur after further amendment or SEC action under Section 8(a) of the Securities Act. It is signed on behalf of the company by Founder and Chief Executive Officer Hing C. Wong and other directors and officers, confirming their authorization of the updated registration materials.
HCW Biologics Inc. is seeking to raise up to $10,000,000 through a reasonable best efforts offering of up to 9,523,810 shares of common stock, pre-funded warrants, or a combination, at an assumed price of $1.05 per share.
The company is a clinical-stage immunotherapy developer focused on chronic inflammation and age-related diseases, with lead candidate HCW9302 now in a first-in-human Phase 1 trial for alopecia areata. A 1-for-40 reverse stock split and prior warrant inducement generated additional flexibility and about $4.0 million of gross proceeds.
HCW Biologics reports cash and cash equivalents of $1.1 million as of September 30, 2025 and cumulative net losses of $106.5 million, with substantial doubt about its ability to continue as a going concern. Payables include $19.4 million of obligations, notably legal fees and construction-related amounts tied to a manufacturing facility dispute.
The company has restructured a global license for HCW11-006 with Trimmune, targeting $7.0 million in combined cash and equity consideration if closing occurs. Nasdaq has granted continued listing subject to the company maintaining compliance with equity and other listing rules through February 16, 2026 under a one-year Panel Monitor period.
HCW Biologics Inc. filed a resale registration statement on Form S-1 covering up to 3,400,033 shares of common stock. These shares include 253,083 Conversion Shares issued when noteholders converted approximately $6.6 million of senior secured notes, up to 126,540 shares issuable upon exercise of related Conversion Warrants, and 3,020,410 Warrant Shares issuable upon exercise of New Warrants held by Armistice Capital Master Fund Ltd. We are told the company will not receive proceeds from selling stockholders’ resales.
The filing describes prior warrant inducement transactions that generated approximately $4.0 million in gross proceeds and a Nasdaq listing history in which HCW regained compliance but must now demonstrate compliance with equity and other rules by December 31 2025 and February 16 2026. The prospectus highlights substantial dilution risk from warrant and share resales, material doubt about the company’s ability to continue as a going concern given $1.1 million in cash as of September 30 2025, and about $19.4 million of past-due obligations, including legal fees and construction payables tied to mechanics lien and foreclosure litigation.
HCW also outlines its immunotherapy pipeline, a key license and co-development deal for preclinical molecule HCW11-006 that could yield a $7.0 million upfront package, and initiation of a Phase 1 trial of lead candidate HCW9302 in alopecia areata.